ArticleOpen forum infectious diseases2025
Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024).
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ongoing high-risk behaviors continue to fuel HCV transmission among men who have sex with men (MSM), challenging elimination efforts. We studied HCV epidemiology in MSM with HIV (MSM-WH) and without HIV in the region of Madrid. Methods: This prospective study (2022-2024) enrolled MSM-WH from 10 centers and MSM on PrEP from an STI clinic. Visits were scheduled at baseline, 3, 6, 9, and 12 months (PrEP group), or baseline, 6, and 12 months (HIV group). Assessments included liver enzymes, HCV serology, HCV-RNA, and STI screening (syphilis, chlamydia, and gonorrhea by PCR). Results: A total of 1372 MSM (733 with HIV; 639 on PrEP) were enrolled. Baseline HCV prevalence was 1.68%, significantly higher in those with prior HCV exposure (5.60% vs 0.72%; prevalence ratio: 7.72, 95% CI: 3.31-18.03). Over 1240.4 person-years (PY) of follow-up, overall HCV incidence was 1.45/100 PY. Primary infection incidence was 0.79/100 PY: 0.94 in PrEP users versus 0.65 in MSM-WH (IRR: 1.44, 95% CI: .24-9.80). Reinfection incidence was 4.32/100 PY overall: 12.90 in PrEP users and 4.05 in MSM-WH (IRR: 3.21, 95% CI: .07-22.53). Two participants experienced within study reinfection (8.7/100 PY, 95% CI: 1.05-31.4). Slamsex and condomless receptive anal intercourse with ≥4 partners were independently associated with HCV infection and reinfection. Conclusions: MSM with prior HCV exposure had markedly higher HCV prevalence and incidence, regardless of HIV status. Risky sexual behaviors remain key drivers of HCV transmission. Behavior-informed prevention strategies are critical to sustain elimination efforts in MSM populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.